Lannett Company Inc (NYSE: LCI), a company that manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced its financial results for the fiscal 2020 third quarter ended 31 March 2020, on Wednesday.
The company reported on a GAAP basis, net sales at USD144.4m for the fiscal 2020 third quarter, compared with USD172.8m in the same period in fiscal 2019.
Gross profit was USD41.7m, or 29% of net sales, compared with USD65.3m, or 38% of net sales in the year-ago period.
Net loss was USD16.6m, or USD0.43 per share, versus net income of USD10.6m, or USD0.27 per diluted share, for the third quarter of fiscal 2019.
'For our fiscal 2020 third quarter, net sales were higher than expected due to COVID-19, as patients appear to have purchased extra supply of their medications and some customers increased their purchases of some of our products to address patient demand and avoid shortages.' said Tim Crew, Lannett chief executive officer. 'We plan to launch several new products in the next several months, and look forward to our scheduled meeting in early June with the FDA to plan next steps for the clinical advancement of our biosimilar insulin glargine partnered product candidate.'
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling